Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma – a multicenter phase 2 trial (EPOC1802)

Medicine, Oncology, Life Sciences, Immunology,
Atezolizumab   Esophageal squamous cell carcinoma   Chemoradiotherapy   Immunotherapy   Unresectable tumors  

Background Esophageal cancer ranks as the seventh most prevalent cancer globally and is the sixth leading cause of cancer-related deaths, accounting for over half a million deaths annually. Esophageal Squamous Cell Carcinoma (ESCC) is one of the primary types of esophageal cancer, particularly prevalent in Asian regions. For patients with unresecta...

Neoadjuvant Cabozantinib for Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma: A Phase 2 Trial

Medicine, Urology, Nephrology, Oncology, Life Sciences, Immunology,
renal cell carcinoma   cabozantinib   neoadjuvant therapy   locally advanced   clinical trial  

Academic Background Renal Cell Carcinoma (RCC) is one of the cancers with a rapidly rising incidence globally, particularly among young patients and minorities. In the United States, an estimated 81,610 new cases of RCC will be diagnosed in 2024, with approximately 30% progressing to metastatic RCC. For locally advanced RCC, the initial treatment i...

Association of the Immediate Perioperative Dynamics of Circulating DNA Levels and Neutrophil Extracellular Traps Formation in Cancer Patients

Medicine, Basic Medical Sciences, Oncology, Life Sciences, Immunology,
circulating DNA   perioperative period   neutrophil extracellular traps   neutrophil elastase   myeloperoxidase   minimal residual disease  

Academic Background Circulating DNA (cirdna) has garnered significant attention in recent years for its potential in tumor diagnosis, particularly in the field of liquid biopsy. cirdna not only aids in detecting tumor gene mutations but also plays a crucial role in treatment monitoring, cancer recurrence surveillance, and cancer screening. However,...

TP53-Specific Mutations Serve as a Potential Biomarker for Homologous Recombination Deficiency in Breast Cancer: A Clinical Next-Generation Sequencing Study

Medicine, Oncology, Life Sciences, Cell Biology, Biochemistry, Immunology, Genetics,
next-generation sequencing   homologous recombination deficiency   TP53   breast cancer   biomarker  

Breast cancer is one of the most common malignant tumors among women worldwide, with a complex pathogenesis involving multiple gene mutations and signaling pathway abnormalities. Homologous Recombination Deficiency (HRD) is a significant molecular characteristic in breast cancer, closely related to patients’ sensitivity to PARP inhibitor (PARPi) th...

Cell-Free Tumor DNA Analysis in Advanced or Metastatic Breast Cancer Patients: Mutation Frequencies, Testing Intention, and Clinical Impact

Medicine, Oncology,
cell-free tumor DNA   breast cancer   mutation frequencies   clinical impact   genetic testing  

Academic Background Breast cancer is one of the most common cancers among women worldwide, particularly advanced or metastatic breast cancer, which is challenging to treat and has a poor prognosis. With the development of precision medicine, the role of molecular biomarkers in breast cancer treatment has become increasingly prominent. Circulating t...

Epstein–Barr Virus Infection Exacerbates Ulcerative Colitis by Driving Macrophage Pyroptosis via the Upregulation of Glycolysis

Medicine, Infectious Diseases, Gastroenterology, Life Sciences, Immunology,
Epstein-Barr virus   ulcerative colitis   macrophages   pyroptosis   glycolysis  

Academic Background Ulcerative Colitis (UC) is a chronic inflammatory bowel disease characterized by recurrent inflammation and ulceration of the colonic mucosa. Current treatments for UC primarily rely on immunosuppressive drugs, such as corticosteroids, immunomodulators, and biologics. However, the immunosuppressive properties of these drugs incr...